Development of New Deep Venous Thrombosis While on Apixaban

The efficacy of novel oral anticoagulants (NOACs) in preventing deep venous thrombosis (DVT) has been established in large multicenter trials. Predictable pharmacokinetics, avoidance of routine laboratory monitoring, and lesser drug interactions have made NOACs safer and more tolerable treatment opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Munish, Ramanathan, Sabarina, Khalighi, Koroush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496103/
https://www.ncbi.nlm.nih.gov/pubmed/28713598
http://dx.doi.org/10.1155/2017/2842935
_version_ 1783247902071586816
author Sharma, Munish
Ramanathan, Sabarina
Khalighi, Koroush
author_facet Sharma, Munish
Ramanathan, Sabarina
Khalighi, Koroush
author_sort Sharma, Munish
collection PubMed
description The efficacy of novel oral anticoagulants (NOACs) in preventing deep venous thrombosis (DVT) has been established in large multicenter trials. Predictable pharmacokinetics, avoidance of routine laboratory monitoring, and lesser drug interactions have made NOACs safer and more tolerable treatment option in comparison to warfarin. However, cases of treatment failure mainly due to interindividual variation in plasma drug levels can be seen rarely. In this report we describe a case of acute DVT of right lower extremity in a patient who was on apixaban for prevention of venous thromboembolism (VTE) due to underlying nonvalvular atrial fibrillation (NVAF).
format Online
Article
Text
id pubmed-5496103
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-54961032017-07-16 Development of New Deep Venous Thrombosis While on Apixaban Sharma, Munish Ramanathan, Sabarina Khalighi, Koroush Case Rep Cardiol Case Report The efficacy of novel oral anticoagulants (NOACs) in preventing deep venous thrombosis (DVT) has been established in large multicenter trials. Predictable pharmacokinetics, avoidance of routine laboratory monitoring, and lesser drug interactions have made NOACs safer and more tolerable treatment option in comparison to warfarin. However, cases of treatment failure mainly due to interindividual variation in plasma drug levels can be seen rarely. In this report we describe a case of acute DVT of right lower extremity in a patient who was on apixaban for prevention of venous thromboembolism (VTE) due to underlying nonvalvular atrial fibrillation (NVAF). Hindawi 2017 2017-06-20 /pmc/articles/PMC5496103/ /pubmed/28713598 http://dx.doi.org/10.1155/2017/2842935 Text en Copyright © 2017 Munish Sharma et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sharma, Munish
Ramanathan, Sabarina
Khalighi, Koroush
Development of New Deep Venous Thrombosis While on Apixaban
title Development of New Deep Venous Thrombosis While on Apixaban
title_full Development of New Deep Venous Thrombosis While on Apixaban
title_fullStr Development of New Deep Venous Thrombosis While on Apixaban
title_full_unstemmed Development of New Deep Venous Thrombosis While on Apixaban
title_short Development of New Deep Venous Thrombosis While on Apixaban
title_sort development of new deep venous thrombosis while on apixaban
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496103/
https://www.ncbi.nlm.nih.gov/pubmed/28713598
http://dx.doi.org/10.1155/2017/2842935
work_keys_str_mv AT sharmamunish developmentofnewdeepvenousthrombosiswhileonapixaban
AT ramanathansabarina developmentofnewdeepvenousthrombosiswhileonapixaban
AT khalighikoroush developmentofnewdeepvenousthrombosiswhileonapixaban

Ejemplares similares